Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab.

Dávila, I; Campo, P; Cimbollek, S; Almonacid Sánchez, C; Quirce, S; Moreira, A; Ramirez, A; Soto Campos, G

Dávila, I; Campo, P; Cimbollek, S; Almonacid Sánchez, C; Quirce, S; Moreira, A; Ramirez, A; Soto Campos, G.

Afiliación

Dávila I; Allergy Service, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Campo P; Biomedical and Diagnosis Science Department, Salamanca University School of Medicine, Salamanca, Spain.
Cimbollek S; Allergy Unit, IBIMA-Regional University Hospital of Málaga, Málaga, Spain.
Almonacid Sánchez C; Department of Allergy, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Quirce S; Department of Respiratory Medicine, Ramón y Cajal Hospital, IRYCIS, Alcala de Henares University, Madrid, Spain.
Moreira A; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Ramirez A; CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain.
Soto Campos G; Novartis Farmacéutica, Barcelona, Spain.

J Investig Allergol Clin Immunol ; 32(3): 213-215, 2022 06 20.

Article en En | MEDLINE | ID: mdl-34581281

Asunto(s)

Antiasmáticos; Asma; Antiasmáticos/uso terapéutico; Asma/diagnóstico; Asma/tratamiento farmacológico; Humanos; Omalizumab/uso terapéutico

Palabras clave

Allergens and epitopes; Asthma; Eosinophils; IgE

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Antiasmáticos Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google